Monitoring adverse drug events: The Food and Drug Administration MedWatch reporting system

Regional Anesthesia and Pain Medicine

Volumn 23, Issue 6 SUPPL. 2, 1998, Pages 190-193

  Landow, Laurence ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b A ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXFENFLURAMINE; FENFLURAMINE; LOW MOLECULAR WEIGHT HEPARIN; MIDAZOLAM;

CLINICAL RESEARCH; DRUG APPROVAL; DRUG MARKETING; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MEDICAL SOCIETY; PRIORITY JOURNAL; REGIONAL ANESTHESIA; REVIEW; SPINAL CORD HEMORRHAGE; THROMBOEMBOLISM;

EID: 0031796281     PISSN: 0146521X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1098-7339(98)90146-8     Document Type: Review

References (22)

1. Lazarou J, Pomeranz BH, Corey P. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998: 279: 1200-1205.
2. Finney DJ. Statistical aspects of monitoring for dangers in drug therapy. Methods Inf Med 1971: 10: 1-8.
3. Strom BL, Tugwell P. Pharmacoepidemiology: Current status, prospects, and problems. Ann Intern Med 1990: 113: 179-181.
4. Temple RJ, Jones JK, Crout JR. Adverse effects of newly marketed drugs. N Engl J Med 1979: 300: 1046-1047.
5. Goldman SA, Kennedy DL, Lieberman R. Clinical Therapeutics and the Recognition of Drug-Induced Disease. Rockville, MD; Food and Drug Administration, MedWatch Continuing Education, June 1995.
6. Reeves RP, McCormick DJ, Jepson HT. Practolol metabolism in various small animal species. Xenobiotica 1979: 9: 453-458.
7. U.S. General Accounting Office. FDA Drug Review: Postapproval Risks 1976-85. GAO/PEMD-90-15, April 26, 1990.
8. Lewis JA. Post-marketing surveillance: How many patients? Trends Pharmacol Sci 1981: 2: 93-94.
9. Accreditation Manual for Hospitals, 1993. Oakbrook Terrace, IL, Joint Commission on Accreditation of Healthcare Organizations, 1993.
10. ASHP Guidelines on Adverse Drug Reaction Monitoring and Reporting: Practice Standards of ASHP 1992-93. Bethesda, MD, American Society of Hospital Pharmacists, 1992: 52-53.
11. Rossi AC, Knapp DE. Discovery of new adverse drug reactions: A review of the Food and Drug Administration's Spontaneous Reporting System. JAMA 1984: 252: 1030-1033.
12. Scott HD, Rosenbaum SB, Waters WJ, et al. Rhode Island physicians' recognition and reporting of adverse drug reactions. R I Med J 1987: 70: 311-316.
13. Reinstein PF, Robinson JI. Annual Adverse Drug Experience Report: 1994. Division of Epidemiology and Surveillance, Food and Drug Administration, US Department of Health and Human Services.
14. Kessler DA. Introducing MEDWatch: A new approach to reporting medication and device adverse effects and product problems. JAMA 1993: 269: 2765-2768.
15. American Medical Association. Reporting adverse drug and medical device events: Report of the AMA's Council on Ethical and Judicial Affairs. Food Drug Law J 1994: 49: 359-366.
16. Nierenberg DW. Clinical pharmacology instructions for all medical students. Clin Pharm Ther 1986: 40: 483-487.
17. Protecting the identities of reporters of adverse events and patients: Preemption of disclosure rules. Federal Register 1995: 60: 16962-16968.
18. Serradell J, Bjornson DC, Hartzema AG. Drug utilization study methodologies, national and international perspectives. Drug Intell Clin Pharm 1987: 21: 994-1001.
19. Green DM. Pre-existing conditions, placebo reactions, and "side-effects." Ann Intern Med 1964: 60: 255-265.
20. McQuay H, Carroll D, Moore A. Variation in the placebo effect in randomized controlled trials of analgesics: All is as blind as it seems. Pain 1995: 64: 331-335.
21. Reidenberg MM, Lowenthal DT. Adverse nondrug reactions. N Engl J Med 1968: 279: 678-679.
22. Sachs RM, Bortnichak EA. An evaluation of spontaneous adverse drug reaction monitoring systems. Am J Med 1986: 81 (Suppl 5B): 49-55.